Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Picard Medical (PMI) Free Cash Flow (2024 - 2026)

Picard Medical posted quarterly Free Cash Flow of -$3.8 million for Q1 2026, down 70.73% year-on-year from -$13.1 million in Q1 2025, and up 12.59% on a QoQ basis from -$4.4 million in Q4 2025.

Picard Medical (PMI) has 3 years of Free Cash Flow data on file, last reported at -$3.8 million in Q1 2026.

  • For the quarter ending Q1 2026, Free Cash Flow fell 70.73% year-over-year to -$3.8 million; the trailing twelve-month figure through Mar 2026 stood at -$17.3 million (down 115.7% YoY), and the FY2025 full-year result was -$15.7 million, down 31.99% from the prior year.
  • Free Cash Flow for Q1 2026 stood at -$3.8 million, up from -$4.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$2.2 million in Q1 2025 and bottomed at -$6.5 million in Q3 2025.
  • The 3-year median for Free Cash Flow is -$3.2 million (2024), against an average of -$3.6 million.
  • Peak annual rise in Free Cash Flow reached 38.86% in 2025, while the deepest fall reached 149.77% in 2025.
  • A 3-year view of Free Cash Flow shows it stood at -$3.2 million in 2024, then slumped by 38.86% to -$4.4 million in 2025, then grew by 12.59% to -$3.8 million in 2026.
  • The last three Free Cash Flow figures came in at -$3.8 million (Q1 2026), -$4.4 million (Q4 2025), and -$6.5 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Free Cash Flow (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 916.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 415.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 2.30 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 171.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -21.10 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 305.56 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 449.00 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 204.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 245.20 Mn
10 Picard Medical 12.10 Mn 12.10 Mn 275,000.00 -3.83 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -3.83 Mn
Mar 31, 2026 -3.83 Mn
Dec 31, 2025 -4.38 Mn
Dec 31, 2025 -4.38 Mn
Sep 30, 2025 -6.51 Mn
Sep 30, 2025 -6.51 Mn
Dec 31, 2024 -3.15 Mn
Dec 31, 2024 -3.15 Mn
Sep 30, 2024 -2.61 Mn
Sep 30, 2024 -2.61 Mn